Nov 20 (Reuters) – France has negotiated a big
discount for Gilead Sciences Inc’s controversial new
hepatitis C drug Sovaldi, under a government deal that ensures
it will be fully reimbursable by health-funding schemes.
The Economic Committee for Health Products (CEPS) has fixed
the price of a box of Sovaldi at 13,667 euros before tax, a
reduction of 5,000 euros on the original price and “the lowest
price in Europe”, the Health Ministry said on Thursday.
Twelve weeks of treatment will now cost 41,000 euros
($51,373) before tax, against 56,000 euros previously.
PARIS (Reuters) – France will tax drugmakers whose costly hepatitis C
drugs threaten to throw off course its healthcare budget, the
government has said, heaping pressure on pharmaceutical companies like
Gilead Sciences to cut their prices.
The Socialist government said
it had designed a “progressive contribution scheme” ensuring all
patients can access new and more effective treatments against the
liver-destroying virus, while limiting the burden of these drugs on
The government will selectively tax drugmakers
when the total cost to the state from their hepatitis C drugs exceeds a
certain amount each year, Health Minister Marisol Touraine said, as she
unveiled the country’s 2015 social security budget bill on Monday.
France has stopped free treatment of Georgian citizens suffering from
hepatitis C, human rights activist Dmitry Lortkipanidze and executive
director of the Georgian- French friendship association Nugzar
Sulashvili said at a briefing on Tuesday.
“France made this decision on August 6, 2013, after the French
embassy learned a hepatitis C free treatment program was used in
Georgia,” Sulashvili added. “However, it was not indicated that the
program is valid only in the penal system.”
Around 400-5,000 Georgian citizens suffering from hepatitis C are
being treated in France. They are subject to deportation, he said.
With all-oral, interferon-free HCV regimens becoming treatment of choice, Transgene lacks partner for its therapeutic vaccine; company changes focus to HBV
By Ryan McBride for Fierce Biotech
February 8, 2013 – Fierce Biotech – Transgene CEO Philippe Archinard sees no immediate partnership in store for the hep C candidate, TG4040, and is now holding out hope that the therapeutic vaccine could find work in markets such as China where the adoption of new pills for the disease might be slower than major markets in the West, he told Bloomberg. And his company, backed by the wealthy Merieux family, has shifted focus to an experimental vaccine for hepatitis B.
Transgene has developed the hep C vaccine for use with the standard injected therapy interferon, which causes flu-like symptoms that have kept many patients on the sidelines waiting for the new all-oral regimens that work quickly and could reduce adverse side effects. The field of interferon-free contenders moved quickly in a race to bring cures to the market, which is expected to explode with the expected arrival of the pills over the next several years.